The Association between Plasma Levels of Intact and Cleaved uPAR Levels and the Risk of Biochemical Recurrence after Radical Prostatectomy for Prostate Cancer

The Association between Plasma Levels of Intact and Cleaved uPAR Levels and the Risk of Biochemical Recurrence after Radical Prostatectomy for Prostate Cancer

Radical prostatectomy (RP) is a curatively intended treatment option for clinically localized non-metastatic prostate cancer (PCa). Novel biomarkers could refine treatment choice based on a better identification of men at risk of biochemical recurrence (BCR) following therapy. The urokinase plasmino...

Full description

Bibliographic Details
Main Authors:	Hein Vincent Stroomberg, Gitte Kristensen, Kasper Drimer Berg, Solvej Lippert, Klaus Brasso, Martin Andreas Røder
Format:	Article
Language:	English
Published:	MDPI AG 2020-10-01
Series:	Diagnostics
Subjects:	prostate cancer urokinase plasminogen activator receptor biochemical recurrence radical prostatectomy
Online Access:	https://www.mdpi.com/2075-4418/10/11/877

Similar Items

Targeting uPAR in diabetic vascular pathologies*
by: Martyna Durak-Kozica, et al.
Published: (2019-12-01)

Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor – β1 (TGF-β1) and potential effects on migration and invasion
by: Synnove Norvoll Magnussen, et al.
Published: (2017-05-01)

Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications
by: Niaz Mahmood, et al.
Published: (2018-02-01)

A study of the interaction between Helicobacter pylori and components of the human fibrinolytic system
by: A. Yarzábal, et al.
Published: (2000-09-01)

Serum levels of urokinase-type plasminogen activator in healthy dogs and oncologic canine patients
by: Sofia C. Ramos, et al.
Published: (2017-08-01)

Development of AE147 Peptide-Conjugated Nanocarriers for Targeting uPAR-Overexpressing Cancer Cells
by: Park JY, et al.
Published: (2021-08-01)

5hmC Level Predicts Biochemical Failure Following Radical Prostatectomy in Prostate Cancer Patients with ERG Negative Tumors
by: Gitte Kristensen, et al.
Published: (2019-02-01)

Urokinase-type plasminogen activator is a modulator of synaptic plasticity in the central nervous system: implications for neurorepair in the ischemic brain
by: Manuel Yepes
Published: (2020-01-01)

Evaluation of Urokinase Plasminogen Activator Receptor, Soluble Urokinase Plasminogen Activator Receptor, and β1 Integrin in Patients with Hodgkin′s Lymphoma
by: Shirin Kouhpayeh, et al.
Published: (2017-01-01)

Activación y determinación de parámetros cinéticos de la Plasmina Humana y Ovis aries
by: Omaira Cañas, et al.
Published: (2011-01-01)

CRISPR/Cas9 uPAR Gene Knockout Results in Tumor Growth Inhibition, EGFR Downregulation and Induction of Stemness Markers in Melanoma and Colon Carcinoma Cell Lines
by: Alessio Biagioni, et al.
Published: (2021-05-01)

uPAR PET/CT for Prognostication and Response Assessment in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing Radium-223 Therapy: A Prospective Phase II Study
by: Marie Øbro Fosbøl, et al.
Published: (2021-06-01)

The Contribution of the Urokinase Plasminogen Activator and the Urokinase Receptor to Pleural and Parenchymal Lung Injury and Repair: A Narrative Review
by: Torry A. Tucker, et al.
Published: (2021-02-01)

Fibrinolysis protease receptors promote activation of astrocytes to express pro-inflammatory cytokines
by: Paola Pontecorvi, et al.
Published: (2019-12-01)

Fibrinolysis regulation by platelets retaining plasminogen and tissue-type plasminogen activator on their surface
by: T. Grinenko, et al.
Published: (2019-12-01)

Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors
by: Lampelj Maja, et al.
Published: (2015-12-01)

Proteolytic enzyme and adiponectin receptors as potential targets for COVID-19 therapy
by: K. A. Rubina, et al.
Published: (2021-05-01)

Inhibitory effects of wogonin on invasion by human oral cancer cells by decreasing the activity of matrix metalloproteinases and urokinase-plasminogen activator
by: Yung-Chuan Ho, et al.
Published: (2014-06-01)

Concentrations of plasminogen activator inhibitor-1 (PAI-1) and urokinase plasminogen activator (uPA) in induced sputum of asthma patients after allergen challenge
by: Krzysztof Kowal,, et al.
Published: (2010-04-01)

Reduced Expression of Urokinase Plasminogen Activator in Brown Adipose Tissue of Obese Mouse Models
by: Chung-Ze Wu, et al.
Published: (2021-03-01)

Specific inhibitors of urokinase plasminogen activator for treatment of cancers; In silico approach
by: Benjamin Talbot, et al.
Published: (2020-05-01)

Bispecific Targeting of EGFR and Urokinase Receptor (uPAR) Using Ligand-Targeted Toxins in Solid Tumors
by: Felix Oh, et al.
Published: (2020-06-01)

Urokinase plasminogen activator expression in canine malignant mammary tumours by immunohistochemical study
by: Golshahi Hannaneh, et al.
Published: (2013-12-01)

Soluble urokinase plasminogen activator receptor and its complicated role in hemodialysis (HD) patients with Covid-19 infection
by: Ioannis Griveas, et al.
Published: (2021-07-01)

Expression patterns of uPAR, TF and EGFR and their potential as targets for molecular imaging in oropharyngeal squamous cell carcinoma
by: Charabi, B.W, et al.
Published: (2022)

Complications after radical prostatectomy: our experiences
by: Klemen Jagodič, et al.
Published: (2007-12-01)

The factors predicting biochemical recurrence in patients with radical prostatectomy
by: Osman Koca, et al.
Published: (2016-01-01)

Experimental and Clinical Evidence Supports the Use of Urokinase Plasminogen Activation System Components as Clinically Relevant Biomarkers in Gastroesophageal Adenocarcinoma
by: Gary Tincknell, et al.
Published: (2021-08-01)

Effect of remission induction therapy on the level of soluble urokinase plasminogen activator receptor in acute myeloid leukemia
by: Eman Qassim Ahmed, et al.
Published: (2020-01-01)

Populationsbiologische und pathogenetische Aspekte von Neisseria meningitidis
by: Weber, Martin V. R. H.
Published: (2007)

Advances on the components of fibrinolytic system in malignant tumors
by: Zengzheng Ge, et al.
Published: (2019-01-01)

The effect of anti-human plasminogen monoclonal antibodies on Glu-plasminogen activation by plasminogen activators
by: M. Akrami, et al.
Published: (2006-07-01)

Plasminogen Activators in Neurovascular and Neurodegenerative Disorders
by: Manuel Yepes, et al.
Published: (2021-04-01)

Fibrinolytics: from the thrombolysis to the processes of blood vessels growth and remodeling, neurogenesis, carcinogenesis and fibrosis
by: V A Tkachuk, et al.
Published: (2019-09-01)

Monitoring of chemotherapy successfulness of Platina/Taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II
by: Dženita Ljuca, et al.
Published: (2007-05-01)

Analysis of factors affecting first serum prostate specific antigen level after radical prostatectomy for prostate cancer
by: ZHANG Jingqi, et al.
Published: (2019-08-01)

suPAR na avaliação do prognóstico após permanência na unidade de terapia intensiva: um estudo piloto
by: Joana Silvestre, et al.
Published: (2019-01-01)

Evaluation Of Tumor Regulatory Genes And Apoptotic Pathways In The Cytotoxic Effect Of Cytochalasin H On Malignant Human Glioma Cell Line (U87MG)
by: Samaneh Heidarzadeh, et al.
Published: (2018-12-01)

The unique invasiveness of glioblastoma and possible drug targets on extracellular matrix
by: Hatoum A, et al.
Published: (2019-02-01)

Effect of age on biochemical recurrence after radical prostatectomy
by: Cuneyt Ozden, et al.
Published: (2017-02-01)

Cannot write session to /tmp/vufind_sessions/sess_qvktr4451lolf4bfoovt9s3bqb